Pharmacy Benefit Managers (PBMs) are “powerful middlemen inflating drug costs and squeezing Main Street pharmacies,” according to a new report from the Federal Trade Commission (FTC).
The agency released an interim report on its two-year investigation into PBMs detailing ways these corporate middlemen are profiting at the expense of patients and community pharmacies.
Here are five key takeaways from the report:
- A few PBMs dominate the market. “...increasing vertical integration and concentration consolidation has enabled the six largest PBMs to manage nearly 90 percent of all prescriptions filled in the United States.”
- PBMs and insurers are often the same company. “...five of the top six PBMs are now part of corporate healthcare conglomerates that also own and operate some of the nation’s largest health insurance companies, including three of the five largest health insurers in the country.”
- PBMs put profits before patients. “This vertically integrated and concentrated market structure has allowed PBMs to profit at the expense of patients and independent pharmacists.”
- PBMs have incredible power and influence. “PBMs wield enormous power over patients’ ability to access and afford their prescription drugs, allowing PBMs to significantly influence what drugs are available and at what price.”
- PBMs engage in self-preferencing, unfair practices. “Vertically integrated PBMs appear to have the ability and incentive to prefer their own affiliated businesses, creating conflicts of interest that can disadvantage unaffiliated pharmacies and increase prescription drug costs.”
The media and policymakers quickly took note of the FTC’s findings. Here’s a look at what some are saying:
NYT: FTC Says Middlemen Appear to Be Driving Up Drug Prices
Driving up costs: “The FTC’s report detailed an array of ways that benefit managers appeared to be inflating the cost of prescription drugs.”
Calls for reform: “The agency’s findings could also fuel legislative efforts in Congress and in the states to impose limits on the industry.”
WSJ: Big Pharmacy-Benefit Managers Increase Drug Costs, FTC Says
Restricting access: “The FTC said PBMs have excluded from formularies drugs that would cost health plans less in exchange for larger rebates from drugmakers. The restrictions could also force certain patients, depending on the drug and their health plan, to pay more out-of-pocket for medicines than if their plan had preferred a generic.”
Axios: FTC Report Adds to Scrutiny of Drug Middlemen
Vertical integration: “The findings underscore the degree to which vertical integration and concentration among pharmacy benefit managers allow the companies to influence the drug supply chain, potentially driving up cost to patients.”
Reuters: Middlemen Have Outsized Influence on US Drug Prices Due to Market Consolidation, FTC Says
Control over patients: “PBMs set which drugs are covered by insurance and at what price, as well as which pharmacies patients can use to fill their prescriptions. They do this without transparency or public accountability, the report said.”
STAT: FTC Report Finds PBMs Profit at the Expense of Patients and Independent Pharmacies
Anticompetitive tactics: “[PBMs] favor their own pharmacies while excluding rivals and also adjusting formularies, sometimes by designating drugs as specialty medicines.”
Bloomberg: Drug Middlemen Pay Higher Prices To Their Own Pharmacies, FTC Says
Profits before patients: “Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least $1 billion in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission found in an interim study.”
POLITICO: FTC: Biggest PBMs Dole Out Nearly All Prescriptions in US
Consolidated power: “Six major pharmacy benefit managers filled 95 percent of all prescriptions in the U.S., a long-awaited government report finds.”
Calls for transparency: “The report comes as lawmakers on both sides of the aisle have sought to increase transparency on how PBMs conduct business."
I’ve long warned that the 3 big middlemen that control 80% of drug claims are padding their profits, forcing patients to pay higher drug prices & driving pharmacies out of business. @FTC's investigation confirms it. I’m glad @linakhanFTC is taking action.
BREAKING: The @FTC today confirms what pharmacists and patients have been saying all along - PBMs are bad actors that reduce access to quality, affordable health care. It’s time to bust up this monopoly.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
Insurers blame GLP-1s for rising costs. The data tells a different story.
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
Nearly 1 in 4 patients initially denied access to IRA medicines
Message to USAging: Providers are raising concerns about coverage barriers
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
Survey confirms too many insured Americans face barriers to reliable health care
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
Hospitals drive nearly 80% of the U.S. health spending gap
No hassle, hidden markups or fees: AmericasMedicines.com
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
Separating fact from fiction in the medicine supply chain
50-state poll says Americans are concerned that hospital markups hurt patients
Three things you should know from the insurer CEO congressional hearings
Can’t get your medicine? Don’t count on your insurer.
Stop, collaborate and re-evaluate: ICER’s pricing report
California’s landmark PBM crackdown: A wake-up call for reform
Middlemen mark up drug prices and keep discounts meant for you
Putting patients first: Breaking down barriers to care
Direct purchase programs can lower costs for patients
PBMs say they want lower priced medicines, so why don’t they cover them?
Historic biopharmaceutical investments: A prescription for America’s future
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
PBMs are hiding hurdles to essential care
New study: PBMs and commercial insurers are quietly blocking prescription access
North Carolina puts patients first with rebate pass-through law
PBMs, not patents, are blocking access to lower-cost medicines
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
Foreign first pricing schemes don’t address why Americans pay more
The AHIP premium dollar corrected (again)
PBMs launch new ad campaign to block reforms
When middlemen own it all, patients pay the price
3 myths critics get wrong about intellectual property
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Congress Keeps PBMs in the Hot Seat
Wrapping up the J.P. Morgan Healthcare Conference
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
PhRMA CEOs Tee Up Next Week's Health Care Conference
New study: Entities that don’t make medicines get half of what is spent on those medicines
Three things to know about 340B contract pharmacies
The PBM industry's desperate attempt to stop reform
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Guest Post: My health care vote
Insurers continue shifting more costs on to patients
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
ICYMI: The powerful companies driving local drugstores out of business
Hispanic Heritage Month: Fighting for Hispanic patients
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
Key voter insights two months from Election Day
Patient priorities in the 2024 election
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
ICYMI: What patients care about this election year
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
ICYMI: Health care policy should be driven by patients, not politics
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
Ongoing federal probes shed light on PBM and insurer practices
WTAS: The consequences of consolidation and vertical integration
Insurance data: PBM reform has no material impact on premiums
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
3 Takeaways from POLITICO’s Health Care Summit
PBMs using 340B program to drive profits at patients’ expense
Four years later, Maryland board still hasn’t delivered for patients
How the 340B program became a PBM giveaway
ICYMI: When middlemen get in the way, it’s the patients who lose
Get the facts on PCMA’s newest attempt to avoid accountability
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
One year to Election Day: Four voter priorities to watch
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
New poll shows strong bipartisan support for PBM reform
4 truths about state government price setting
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
New analysis shows PBMs use fees as a profit center
It’s PBMs, not patents, blocking competition
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
ICYMI: PBM exec admits choosing profits over patients
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
4 Things to know about PhRMA’s new 50-state poll
New PhRMA ad campaign sheds light on PBM abuses
Three facts about health care spending
AHIP’s latest misinformation campaign & what it’s trying to hide
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
States can support access to medicine as COVID-19 Public Health Emergency ends
Arkansas puts patients first with new share the savings law
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
Holding pharmacy benefit managers accountable
Stopping pharmacy benefit managers from “gaming the system”
Senate hearing to examine bipartisan reforms to rein in middlemen
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
In their own words: Financial barriers exacerbate access challenges for insured Americans
New data show how insurers and middlemen shift Rx costs onto patients
In their own words: Insured Americans struggle to navigate complex coverage
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
Navigating the patient experience: Burdens and barriers standing between patients and their care
Insulin and reconciliation
Patients win as West Virginia implements first-in-nation share the savings policy
3 things voters are concerned about when it comes to their health care coverage
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Government price setting won’t stop insurers from shifting costs to patients
New insulin report highlights how incentives benefit middlemen, harm patients
Key facts: The final rebate rule will be a positive change for patients
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
Study finds middlemen excluded nearly 850 medicines from formularies this year
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Five key facts about the market for insulins
The PBM story you haven’t heard: Hidden fees quadrupled in two years
OptumRX: Sharing rebates with patients is “worth it”
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
Why won’t the insurance industry tell the truth about medicine costs?
FTC report confirms PBMs profit at the expense of patients
PBMs/Insurance
FTC report confirms PBMs profit at the expense of patients
FTC report confirms PBMs profit at the expense of patients